Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (1 records) with 2024 (1) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
Endotoxin and bioburden control sits at the intersection of pharmaceutical quality control, analytical chemistry and, increasingly, digital manufacturing execution. The search underlying this page combines detection and depyrogenation terms — recombinant factor C, action limit, recovery study — with the operational language of water systems, sampling plans and hold-time limits, capturing both the assay science and the manufacturing controls built around it.
142 published records across 2015 to mid-2026 form the base of this analysis, spanning material-testing methods, cosmetics and medicinal-preparation uses, and a smaller but distinct cluster of control-system and connectivity filings tied to manufacturing execution.
Pick a task. Every answer cites the patents behind it.
Two views of the same 142-record set: how filing activity has moved year over year, and how those records break down across IPC subclasses.
Annual filings ran from 3 in 2017 to a peak of 18 in 2018, and by the 2021–2024 window growth was flat at 0% (1 filing in 2021, 1 in 2024). 2025 and 2026 counts are still incomplete because publication typically lags filing by around 18 months, so the visible tail should not be read as a slowdown.
G01N (material analysis and testing) accounts for 52.8% of the 142 records, well ahead of G05B control systems (12.7%), A61K medicinal preparations (11.3%) and A61Q cosmetics use (10.6%). C12Q enzyme/DNA-based testing, H04L digital transmission, G06F data processing and H04W wireless networks each sit at 9.9% or below, marking the smaller, more specialised branches of the field.
Shares are the percentage of the 142 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about endotoxin and bioburden control and every answer comes back with the patent numbers behind it.
Try EurekaThe invention relates to unmasking endotoxins in compositions so that previously present, but undetectable endotoxins are rendered detectable.Filed by Biomérieux Deutschland, published 2017-08-10.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2008063503A2 | Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin … | 58 |
| 2 | US20080248508A1 | Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin … | 58 |
| 3 | US20200133224A1 | Cloud-Controlled Manufacturing Execution System (CLO-cMES) for use in pharmaceutical manufacturing process co… | 30 |
| 4 | WO2011146463A2 | Enhancing endotoxin detection | 29 |
| 5 | US20150060272A1 | Amperometric detection of limulus amebocyte lysate activation by endotoxin and/or 1-3-beta-d-glucan | 27 |
| 6 | WO2017004534A2 | Microbiome-compatible cosmetics | 18 |
| 7 | US20080221722A1 | Methods of interfacing nanomaterials for the monitoring and execution of pharmaceutical manufacturing process… | 15 |
| 8 | US20080294361A1 | Intelligent execution system for the monitoring and execution of vaccine manufacturing | 10 |
| 9 | US20180369129A1 | Microbiome-compatible cosmetics | 9 |
| 10 | US20100217425A1 | Manufacturing execution system (MES) and methods of monitoring glycol manufacturing processes utilizing funct… | 7 |
Citation counts reflect influence within the searched corpus and skew toward older records; they are not a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three patterns stand out once the filing trend, technology mix and citation data are read together.
The leading assignee holds 39 records against 14 at fifth place in a 24-company ranking, a gap wide enough that competitive tracking should treat this filer as the benchmark rather than one of several peers.
Filings held at 1 in both 2021 and 2024, a 0% change across that span. Combined with 2025-2026 data still filling in, the field reads as steady rather than expanding.
Over half of all records touch G01N material analysis and testing, meaning new filers face the densest prior art there. Control systems, cosmetics and enzyme-based testing each occupy a tenth or less of the record base.
The two most-cited records both concern ultra-low-endotoxin chitosan products, each cited 58 times. Their age within the corpus means high citation counts mark historical influence on the field's assay science, not current filing direction.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to endotoxin and bioburden control, with the prior art for and against each one.
The assignee ranking is dominated by one filer with a long tail behind it; the technology mix points to specific branches that remain lightly claimed.
The top assignee's 39 records outpace the rest of the 24-company ranking by a wide margin, with fifth place at 14 and tenth place at just 2, indicating a long tail of smaller and single-filing entrants.
The strongest co-assignee pairs link a drug-development centre with marine-research and university partners, suggesting institutional research collaboration rather than broad industry cross-licensing.
Every assignee tracked for recent-year momentum, including the ranking leader, shows zero filings in the latest year, consistent with the general publication lag rather than a genuine stop in R&D.
| Assignee | Recent year | YoY |
|---|---|---|
| Hyglos Invest GmbH | 0 | — |
| SMP LOGIC SYST | 0 | -100% |
| AOBiome LLC | 0 | — |
| BIOMERIEUX DEUT GMBH | 0 | — |
| Center for Drug Research and Development (CIDEM) | 0 | — |
| CENT DE INVESTIGACIONES MARINAS | 0 | — |
| University of Havana | 0 | — |
| VEGA HURTADO YAMILE | 0 | — |
The dataset points to a concentrated leader, a flat-but-steady filing trend, and specific under-claimed branches. The next step is turning that into a filing or freedom-to-operate decision.
With one assignee holding 39 of the ranked records, any new filing in material-analysis-based endotoxin detection should be checked against that portfolio's claim scope before drafting.
Explore assignee portfolios in EurekaWireless-linked sensing, cloud-based release control and enzyme-based rapid assays each carry comparatively few filings; a targeted search can confirm whether a first claim is realistic there.
Run a white-space search in EurekaOne assignee leads the ranked field with 39 records, well ahead of the fifth-ranked company at 14 and the tenth at just 2. This gap indicates a single company has built a substantially larger portfolio than the rest of the 24 companies in the ranking. The long tail below the leader consists mostly of smaller filers, some with only a handful of records, so competitive monitoring should prioritise the top of the ranking rather than treat the field as evenly contested.
Filing activity peaked at 18 records in 2018 and has not returned to that level since. Between 2021 and 2024, the last year that can be treated as complete, filings held flat at 1 record in each year, a 0% change. Because publication typically lags filing by around 18 months, the lower counts visible in 2025 and 2026 reflect incomplete data rather than an actual drop in R&D activity, so the honest read is a steady, low-volume field rather than a declining one.
Material analysis and testing, IPC class G01N, covers 52.8% of the 142 records in scope, making it by far the most heavily claimed area. Control and regulating systems (G05B), medicinal preparations (A61K) and cosmetics use (A61Q) each account for roughly 11-13% of records, with enzyme- and DNA-based testing, digital transmission, data processing and wireless networking each below 10%. New filers should expect the densest prior art in material-analysis methods and comparatively more open space in the digital and connectivity-adjacent classes.
The technology composition data shows several branches sitting well below the 52.8% share held by material analysis and testing: wireless-linked bioburden sensing, cloud-based batch release control, digital hold-time-limit tracking and enzyme-based rapid endotoxin assays each represent a smaller slice of the 142 records. These branches connect the field's core detection science to manufacturing execution and IoT-style monitoring, an intersection that appears in the data but has not been heavily claimed, making it a reasonable starting point for a freedom-to-operate check ahead of drafting.
US20170227529A1, filed by Biomérieux Deutschland and published in 2017, covers methods for unmasking endotoxins in compositions so that endotoxins present but previously undetectable become detectable by standard assays. It sits within the material-analysis and testing cluster that makes up the majority of records in this landscape, and matters as a reference point for any new detection-method claim because masked-endotoxin detection is a well-documented technical route rather than an open one. Teams working on detection-sensitivity improvements should review its claim scope directly before finalising a similar approach.
Go past this page: query the whole endotoxin and bioburden control corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page